Innovus Pharmaceuticals (INNV) Releases Earnings Results

Innovus Pharmaceuticals (OTCMKTS:INNV) issued its earnings results on Tuesday. The company reported ($0.01) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. Innovus Pharmaceuticals had a negative net margin of 51.76% and a negative return on equity of 273.00%. The company had revenue of $7.31 million for the quarter.

INNV stock opened at $0.14 on Thursday. Innovus Pharmaceuticals has a 1 year low of $0.08 and a 1 year high of $0.21. The firm has a market capitalization of $30.77 million, a P/E ratio of -3.42 and a beta of 4.02.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Innovus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 13th. ValuEngine raised shares of Innovus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

Innovus Pharmaceuticals Company Profile

Innovus Pharmaceuticals, Inc, a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality.

See Also: Diversification

Earnings History for Innovus Pharmaceuticals (OTCMKTS:INNV)

Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply